Mirum Pharmaceuticals Inc. (MIRM)
$100.63
$0.80
(0.80%)
As on 03-Sep-2026 16:00EDT
Market cap
$5,943 Mln
Revenue (TTM)
$618 Mln
P/E Ratio
--
P/B Ratio
26.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
341.2
-
Debt to Equity
-72
-
Book Value
$--
-
EPS
$-14.6
-
Face value
--
-
Shares outstanding
60,981,227
6 Years Aggregate
CFO
$-452.83 Mln
EBITDA
$-447.33 Mln
Net Profit
$-556.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
| 27.4 | -5.0 | 9.2 | 35.4 | 56.1 | 42.4 | -- |
|
BSE Sensex*
| -9.4 | -2.4 | 3.2 | -4.8 | 5.5 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
| 91.0 | 39.7 | 51.4 | 22.3 | -8.6 | -28.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mirum Pharmaceuticals (MIRM)
|
100.6 | 5,943.2 | 618.1 | -860.2 | -129.9 | -- | -- | 26.6 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 148.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Mirum Pharmaceuticals (MIRM)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and... minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California. Read more
-
CEO & Director
Mr. Christopher Peetz
-
CEO & Director
Mr. Christopher Peetz
-
Headquarters
Foster City, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Mirum Pharmaceuticals (MIRM)
What is the current share price of Mirum Pharmaceuticals Inc (MIRM) Today?
The share price of Mirum Pharmaceuticals Inc (MIRM) is $100.63 (NASDAQ) as of 03-Sep-2026 16:00 EDT. Mirum Pharmaceuticals Inc (MIRM) has given a return of 56.13% in the last 3 years.
What is the current PB & PE ratio of Mirum Pharmaceuticals Inc (MIRM)?
Since, TTM earnings of Mirum Pharmaceuticals Inc (MIRM) is negative, P/E ratio is not available.
The P/B ratio of Mirum Pharmaceuticals Inc (MIRM) is 26.59 times as on 28-Aug-2026, a 413 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-169.72 |
12.60 |
2024 |
-22.73 |
8.86 |
2023 |
-8.44 |
5.55 |
2022 |
-5.39 |
5.15 |
2021 |
-5.81 |
4.06 |
What is the 52 Week High and Low of Mirum Pharmaceuticals Inc (MIRM)?
The 52-week high and low of Mirum Pharmaceuticals Inc (MIRM) are Rs 130.00 and Rs 63.23 as of 04-Sep-2026.
What is the market cap of Mirum Pharmaceuticals Inc (MIRM)?
Mirum Pharmaceuticals Inc (MIRM) has a market capitalisation of $ 5,943 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Mirum Pharmaceuticals Inc (MIRM)?
Before investing in Mirum Pharmaceuticals Inc (MIRM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.